Last reviewed · How we verify
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab alone or in combination with ipilimumab or relatlimab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Details
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 53 |
| Start date | Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jan 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Cutaneous Melanoma
- Mucosal Melanoma
- Ocular Melanoma
- Stage III Acral Lentiginous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIB Uveal Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IIIC Uveal Melanoma AJCC v7
- Stage IV Acral Lentiginous Melanoma AJCC v6 and v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
- Ipilimumab
- Laboratory Biomarker Analysis
- Nivolumab
- Relatlimab
- Therapeutic Conventional Surgery
Countries
United States